Track topics on Twitter Track topics that are important to you
Hemispherx BioPharma (NYSE American:HEB) CEO Thomas Equels tells Proactive Investors that the biopharma has made significant progress in the study of its flagship drug Ampligen in treating ovarian cancer.
Equels is presenting at the Planet MicroCap Showcase today, in Las Vegas. A live webcast of the presentation can be viewed here:
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...